Literature DB >> 32841935

Performance of the ACR TI-RADS and EU TI-RADS scoring systems in the diagnostic work-up of thyroid nodules in a real-life series using histology as reference standard.

Flavia Magri1,2, Spyridon Chytiris1, Laura Croce1,2,3, Martina Molteni1,2, Giulia Bendotti1,2, Giovanni Gruosso2, Samuel Tata Ngnitejeu4, Manuela Agozzino5, Mario Rotondi1,2, Luca Chiovato1,2.   

Abstract

OBJECTIVE: The ultrasonographic scores EU TI-RADS and ACR TI-RADS were introduced to give the clinicians indications for fine needle aspiration cytology (FNAC). The predictive role of these scores was never evaluated and compared in a surgical series of patients. The aim of this study was to evaluate the ex post diagnostic accuracy of EU TI-RADS and ACR TI-RADS in a real-life series of thyroidectomized patients and to evaluate the 'missing' thyroid cancer following the operational indications of these scores.
DESIGN: Retrospective monocentric cohort study.
METHODS: In total, 255 patients (harboring 304 nodules) undergoing thyroidectomy for benign and malignant thyroid conditions were enrolled. The prevalence of thyroid malignancy for each class of ACR TI-RADS and EU TI-RADS, their diagnostic accuracy, the number of 'unnecessary' FNAC and the number of 'missed' cancers were evaluated.
RESULTS: ACR TI-RADS and EU TI-RADS score had similar and satisfactory accuracy values for predicting thyroid malignancy (AUC: 0.835 for ACR TI-RADS vs 0.827 for EU TI-RADS). The ACR TI-RADS and EU TI-RADS categories (suspicious vs non-suspicious), age, sex and presence of a single nodule significantly and independently predicted the presence of malignancy in a logistic regression model. An ex post analysis according to the indications for FNAC for each score indicated that 31 and 16 cases of cancer would have been missed by ACR TI-RADS and EU TI-RADS scores, respectively.
CONCLUSIONS: ACR TI-RADS and EU TI-RADS display a good performance in predicting thyroid cancer when histology is taken as reference standard, but additional clinical judgement is required to decide the indication for FNAC.

Entities:  

Mesh:

Year:  2020        PMID: 32841935     DOI: 10.1530/EJE-20-0682

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Comparison of Thyroid Imaging Reporting and Data Systems in Malignancy Risk Stratification of Indeterminate Thyroid Nodules.

Authors:  Bo Hyun Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-10-28

2.  Non-Marked Hypoechogenic Nodules: Multicenter Study on the Thyroid Malignancy Risk Stratification and Accuracy Based on TIRADS Systems Comparison.

Authors:  Peteris Prieditis; Maija Radzina; Madara Mikijanska; Mara Liepa; Kaspars Stepanovs; Giorgio Grani; Cosimo Durante; Livia Lamartina; Pierpaolo Trimboli; Vito Cantisani
Journal:  Medicina (Kaunas)       Date:  2022-02-09       Impact factor: 2.430

3.  Validating and Comparing C-TIRADS, K-TIRADS and ACR-TIRADS in Stratifying the Malignancy Risk of Thyroid Nodules.

Authors:  Qingfang Chen; Mingnan Lin; Size Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

4.  Repeat thyroid FNAC: Inter-observer agreement among high- and low-volume centers in Naples metropolitan area and correlation with the EU-TIRADS.

Authors:  Lorenzo Scappaticcio; Pierpaolo Trimboli; Sergio Iorio; Maria Ida Maiorino; Miriam Longo; Laura Croce; Marcello Filograna Pignatelli; Sonia Ferrandes; Immacolata Cozzolino; Marco Montella; Andrea Ronchi; Renato Franco; Mario Rotondi; Giovanni Docimo; Katherine Esposito; Giuseppe Bellastella
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

5.  Testing telediagnostic thyroid ultrasound in Peru: a new horizon in expanding access to imaging in rural and underserved areas.

Authors:  T J Marini; S L Weiss; A Gupta; Y T Zhao; T M Baran; B Garra; I Shafiq; D C Oppenheimer; M S Egoavil; R L Ortega; R A Quinn; J Kan; A M Dozier; L Tamayo; C Carlotto; B Castaneda
Journal:  J Endocrinol Invest       Date:  2021-05-10       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.